Tuesday, April 12, 2016
| Boehringer-Ingelheim- Lunch SessionDabigatran 2016: Innovation in Anticoagulation Care |
|
AstraZeneca – Lunch Session “Prolonged DAPT – Where Do We Stand Post PEGASUS & DAPT Trials?” Hall I |
Sanofi – Lunch Session“PCSK9 Inhibition : Heralding a New Era for Prevention of Cardiovascular Disease” Hall J |
Wednesday, April 13, 2016
|
Pfizer – Lunch Session From RCTs and RWD to your Own Practical Choices Hall H |
|
Novartis – Lunch Session EnTRESTo – Redefine Hheart Failure Treatment Hall I |
|
Bayer – Lunch Session Xarelto – Confidence from Evidence and Real World Experience Hall J |
